SCHEMBL7530264

SCHEMBL7530264

CC(=O)N(c1ccc(/C=C/c2ccc(OC(C)(C)C)c(C(=O)O)c2)cc1)c1ccc(N(C)C(=O)c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.38
RARA P10276 3/20 0.35
RARB P10826 3/20 0.35
RARG P13631 3/20 0.35
NR1H4 Q96RI1 1/20 0.34
PTPN1 P18031 4/20 0.34
PTPN2 P17706 3/20 0.34
PTPN6 P29350 3/20 0.34
MAPT P10636 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 2/20 0.33
GAA P10253 2/20 0.33
RAB9A P51151 2/20 0.33
EGFR P00533 2/20 0.33
APAF1 O14727 1/20 0.33
TDP2 O95551 1/20 0.33
NSD2 O96028 1/20 0.33
CASP3 P42574 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7646325 0.94 APP (0.41) APPRARARARBRARGNR1H4
SCHEMBL7530268 0.93 APP (0.40) APPRARARARBRARGPTPN1
SCHEMBL7530259 0.93 APP (0.40) APPRARARARBRARGPTPN1
SCHEMBL7534171 0.86 NOTUM (0.46) APPNR1H4PTPN1PTPN2PTPN6
SCHEMBL7648645 0.85 PTPN1 (0.44) APPRARARARBRARGPTPN1
SCHEMBL7534165 0.85 PTPN1 (0.44) APPRARARARBRARGPTPN1
SCHEMBL7531123 0.83 PTPN1 (0.53) APPRARARARBRARGPTPN1
SCHEMBL7648595 0.83 MAPT (0.40) MAPTMEN1KMT2ANPC1GAA
SCHEMBL7648629 0.77 PTPN1 (0.38) APPPTPN1PTPN2PTPN6MAPT
SCHEMBL7648639 0.77 NPC1 (0.45) PTPN1MAPTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US disclosed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers SLC2A1, SLC2A8, SLC2A2 APP 4582/4885RARA 2897/4885RARB 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.